Mr. Speaker, we have been very clear about investing and supporting made-in-Canada solutions. The member opposite highlights the important investment that we made at the NRC Royalmount facility. This will enable us to produce up to 24 million doses annually.
We will make sure that we continue to work with the provinces and territories and determine the best path forward to ensure Canadians have access to safe and effective vaccines when they are available.